About: The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses
Creator	Osterrieder, Nikolaus Brosnahan, Margaret Damiani, Armando Erb, Hollis Perkins, Gillian Van De Walle, Gerlinde
Source	Elsevier; Medline; PMC
abstract	Abstract Available vaccines fail to induce lasting and protective immunity to equine herpesvirus 1 (EHV-1) associated diseases. RNA interference is a novel approach showing promise for therapeutic use in outbreak situations. This study examined the effect of small interfering RNA (siRNA) on clinical signs as well as the presence of live virus and viral DNA in nasal secretions and peripheral blood mononuclear cells (PBMCs) in horses experimentally infected with EHV-1. siRNA targeting two EHV-1 genes (glycoprotein B and the origin binding protein) was administered 12h before and 12h after intranasal infection with EHV-1. Control horses received siRNA targeting firefly luciferase. A significantly smaller proportion (0/10) of horses receiving siRNA targeting viral genes required euthanasia due to intractable neurologic disease as compared to horses in the control group (3/4; p =0.01). There was no significant difference in the presence of live virus or viral DNA in the nasal secretions or PBMCs between the two groups. Future studies are necessary to define the relative contributions of host and virus factors in the development of the neurological form of the infection and to determine an optimal dosing regimen for metaphylactic or therapeutic use of siRNA for treating EHV-1 infection.
has issue date	2010-02-28(xsd:dateTime)
bibo:doi	10.1016/j.virusres.2009.10.017
bibo:pmid	19896512
has license	els-covid
sha1sum (hex)	2bc3cdd87d1f68b7672f5b4033de824363c28604
schema:url	https://doi.org/10.1016/j.virusres.2009.10.017
resource representing a document's title	The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses
has PubMed Central identifier	PMC7114471
has PubMed identifier	19896512
schema:publication	Virus Research
resource representing a document's body	covid:2bc3cdd87d1f68b7672f5b4033de824363c28604#body_text
is schema:about of	named entity 'promise' named entity 'This' named entity 'neurologic disease' named entity 'virus' named entity 'treating' named entity 'PBMCs' named entity 'siRNA' named entity 'infection' named entity 'INTRACTABLE' named entity 'COMPARED' named entity 'BINDING PROTEIN' named entity 'SIRNA' named entity 'NEUROLOGICAL' named entity 'HORSES' named entity 'FUTURE' named entity 'EFFECT' named entity 'ADMINISTERED' named entity 'VIRAL DNA' named entity 'NEUROLOGIC DISEASE' named entity 'TARGETING' named entity 'PROMISE' named entity 'IS A' named entity 'INFECTED' named entity 'PERIPHERAL BLOOD MONONUCLEAR CELLS' named entity 'NASAL SECRETIONS' named entity 'PRESENCE OF' named entity 'RNA INTERFERENCE' named entity 'DETERMINE' named entity 'NOVEL' named entity 'GENES' named entity 'DIFFERENCE' named entity 'HOST' named entity '0.01' named entity 'SMALL INTERFERING RNA' named entity 'INTRANASAL INFECTION' named entity 'TREATMENT' named entity 'INFECTION' named entity 'HORSES' named entity 'EXAMINED' named entity 'DISEASES' named entity 'CONTROL' named entity 'CONTROL GROUP' named entity 'STUDIES' named entity 'SIGNIFICANT' named entity 'EXPERIMENTAL' named entity 'DUE TO' named entity 'OPTIMAL' named entity 'TREATING' named entity 'GROUPS' named entity 'RELATIVE' named entity 'PROTECTIVE IMMUNITY' named entity 'ASSOCIATED' named entity 'INDUCE' named entity 'REGIMEN' named entity 'DEVELOPMENT' named entity 'USE OF' named entity 'OUTBREAK' named entity 'FORM' named entity 'SMALLER' named entity 'EUTHANASIA' named entity 'PROPORTION' named entity 'VACCINES' named entity 'FIREFLY LUCIFERASE' named entity 'VIRUS' named entity '283' named entity 'INFECTION' named entity 'LIVE' named entity 'VIRAL GENES' named entity 'THERAPEUTIC USE' named entity 'EQUINE HERPESVIRUS 1' named entity '2F10' named entity 'ORIGIN' named entity 'PBMCS' named entity 'SIRNA' named entity 'REQUIRED' named entity 'NECESSARY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software